RKWD
ROCKWOOD RESEARCH · A CORPORATE FILINGS WEBSITE|STRAIGHT FROM THE SOURCE · SEC EDGAR|SPONSOREDYour message on this tape — bid on the Rockwood Ad Exchange · Rockwood Ad Exchange|
…
Rockwood Research

Corporate filings · Event Monitor · Free for all

← Back

REPLIGEN CORP

RGEN

Biological Products, (No Diagnostic Substances) · SIC 2836 · CIK 0000730272

SHARE:XLINKEDINEMAIL
Revenue FY2025
$0.74B
Net Income
$0.05B
EPS (Basic)
$0.87
Net Margin
6.6%
ROE
2.3%
Total Equity
$2.11B
Shares Out
56M

REPLIGEN CORP — Biological Products, (No Diagnostic Substances). Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2010–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Revenue & Net Income (10Y)

Margin Trends

Investor Ownership · 6 funds in our universe

FundPosition Value% of AUMQoQ ChgWeight
12 West Capital Management
12 West Capital Management
$38.2M
2.8%
+46.5%
Maverick Capital
Lee Ainslie
$270.8M
1.7%
+30.7%
Holocene Advisors
Holocene Advisors
$176.3M
0.3%
+82.3%
Duquesne Family Office
Stanley Druckenmiller
$10.6M
0.2%
NEW
Royce & Associates
Royce & Associates
$23.8M
0.2%
+50.8%
Weitz Investment Management
Wallace Weitz
$5.6M
0.1%
+60.0%

Insider Transactions

Reading stored insider transactions…